Treg对FasL敏感及相对IL-2缺乏驱动特发性再生障碍性贫血免疫功能障碍
本研究探讨特发性再生障碍性贫血(AA)中调节性T细胞(Treg)亚群失衡的机制及治疗干预潜力。研究发现FasL介导的凋亡和相对IL-2缺乏导致Treg组成偏斜,高浓度IL-2可克服这些机制并扩增AA Treg,扩增的Treg高表达p-BCL-2且能抑制GVHD。补充IL-2可能改善AA患者标准免疫抑制治疗的结局。
要点
- AA中Treg减少由FasL介导凋亡和相对IL-2缺乏驱动。
- 高浓度IL-2可在体外扩增AA Treg并使其抵抗凋亡。
- 扩增的AA Treg在炎症环境中保持抑制功能和表型。
核心结论
- FasL介导的凋亡和相对IL-2缺乏是AA中Treg亚群失衡的两种机制。
- IL-2增强可克服这些机制,高浓度IL-2体外扩增的AA Treg高表达p-BCL-2并抵抗凋亡。
- 扩增的AA Treg在异种移植小鼠模型中能抑制T细胞介导的GVHD宏观临床特征和组织表现。
研究设计与样本
- 研究基于AA患者样本的体外Treg扩增培养及异种移植小鼠模型。
主要发现
- AA中Treg组成偏斜由FasL介导的凋亡和相对IL-2缺乏导致。
- 高浓度IL-2用于体外Treg扩增培养时,AA Treg能够扩增。
- 扩增的AA Treg高表达p-BCL-2,使其抵抗凋亡。
- 扩增的AA Treg在异种移植模型中抑制T细胞介导的GVHD宏观临床特征和组织表现。
- 这些Treg在高炎症环境中维持抑制特性和表型。
临床怎么用
- 在体外Treg扩增培养中补充高浓度IL-2或直接向患者递送IL-2,可能改善标准免疫抑制治疗之外的临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idiopathic aplastic anemia (AA) has 2 key characteristics: an autoimmune response against hematopoietic stem/progenitor cells and regulatory T-cells (Tregs) deficiency. We have previously demonstrated reduction in a specific subpopulation of Treg in AA, which predicts response to immunosuppression. The aims of the present study were to define mechanisms of Treg subpopulation imbalance and identify potential for therapeutic intervention. We have identified 2 mechanisms that lead to skewed Treg composition in AA: first, FasL-mediated apoptosis on ligand interaction; and, second, relative interleukin-2 (IL-2) deprivation. We have shown that IL-2 augmentation can overcome these mechanisms. Interestingly, when high concentrations of IL-2 were used for in vitro Treg expansion cultures, AA Tregs were able to expand. The expanded populations expressed a high level of p-BCL-2, which makes them resistant to apoptosis. Using a xenograft mouse model, the function and stability of expanded AA Tregs were tested. We have shown that these Tregs were able to suppress the macroscopic clinical features and tissue manifestations of T-cell-mediated graft-versus-host disease. These Tregs maintained their suppressive properties as well as their phenotype in a highly inflammatory environment. Our findings provide an insight into the mechanisms of Treg reduction in AA. We have identified novel targets with potential for therapeutic interventions. Supplementation of ex vivo expansion cultures of Tregs with high concentrations of IL-2 or delivery of IL-2 directly to patients could improve clinical outcomes in addition to standard immunosuppressive therapy.
引用
- Lim SP, Costantini B, Mian SA, et al. Treg sensitivity to FasL and relative IL-2 deprivation drive idiopathic aplastic anemia immune dysfunction. Blood. 2020. PMID: 32294156. doi:10.1182/blood.2019001347
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。